HIKMA PHARMACEUTICALS PLC financials
HIKMA PHARMACEUTICALS PLC
Country: GB Reporting currency: USD Latest annual report: 2025-12-31
LEI:
549300BNS685UXH4JI75 ISIN: GB00B0LCW083 Financial statements
(USD, as reported — unscaled; 113 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | $3.35B | $3.13B |
| Cost of sales | $1.91B | $1.71B |
| Gross profit | $1.44B | $1.42B |
| Operating profit (EBIT) | $542.0M | $612.0M |
| Finance costs | $107.0M | $167.0M |
| Profit before tax | $519.0M | $455.0M |
| Income tax expense | $112.0M | $93.0M |
| Profit for the year | $407.0M | $362.0M |
| — attributable to owners | $402.0M | $359.0M |
| — attributable to NCI | $5.0M | $3.0M |
| Total comprehensive income | $486.0M | $300.0M |
| Per share | ||
| Basic EPS | $1.82 | $1.62 |
| Diluted EPS | $1.81 | $1.61 |
| Free cash flow / share | $1.06 | $1.77 |
| Cash flow statement | ||
| Cash generated from operations | $560.0M | $689.0M |
| Net cash from operating activities | $436.0M | $564.0M |
| Income taxes paid | $126.0M | $125.0M |
| Net cash from investing activities | -$388.0M | -$381.0M |
| Purchase of PP&E (capex) | $197.0M | $165.0M |
| Purchase of intangibles | $120.0M | $70.0M |
| Net cash from financing activities | -$25.0M | -$188.0M |
| Dividends paid | $188.0M | $178.0M |
| Lease liability payments | $11.0M | $21.0M |
| Balance sheet | ||
| Total assets | $5.67B | $5.13B |
| Non-current assets | $3.03B | $2.87B |
| Property, plant & equipment | $1.40B | $1.28B |
| Right-of-use assets | $44.0M | $48.0M |
| Intangible assets & goodwill | $393.0M | $382.0M |
| Current assets | $2.64B | $2.26B |
| Inventories | $1.11B | $986.0M |
| Trade & other receivables | $1.06B | $949.0M |
| Cash & equivalents | $217.0M | $188.0M |
| Total equity | $2.61B | $2.32B |
| — attributable to owners | $2.59B | $2.31B |
| Non-controlling interests | $13.0M | $11.0M |
| Non-current liabilities | $1.61B | $834.0M |
| Long-term borrowings | $1.45B | $607.0M |
| Lease liabilities (non-current) | $45.0M | $46.0M |
| Current liabilities | $1.45B | $1.98B |
| Short-term borrowings | $106.0M | $642.0M |
| Lease liabilities (current) | $8.0M | $11.0M |
| Trade & other payables | $715.0M | $650.0M |
| Deferred tax liabilities | $16.0M | $18.0M |
| Derived metrics | ||
| Free cash flow | $239.0M | $399.0M |
| Operating margin | 16.2% | 19.6% |
| Net margin | 12.2% | 11.6% |
| Return on equity | 15.6% | 15.6% |
| Cash conversion ratio | 1.07× | 1.56× |
| Capex coverage | 2.21× | 3.42× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -$86.0M | -$112.0M |
| Adjustments For Decrease Increase In Other Assets | -$21.0M | $0 |
| Adjustments For Decrease Increase In Other Current Assets | -$122.0M | $4.0M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -$97.0M | -$144.0M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $238.0M | $168.0M |
| Adjustments For Finance Income Cost | -$24.0M | -$159.0M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -$1.0M | $0 |
| Adjustments For Increase Decrease In Other Current Liabilities | $39.0M | $36.0M |
| Adjustments For Increase Decrease In Other Liabilities | $1.0M | $4.0M |
| Adjustments For Increase Decrease In Trade and Other Payables | $38.0M | $78.0M |
| Adjustments For Provisions | -$3.0M | -$1.0M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | $7.0M | $16.0M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $0 | $150.0M |
| Comprehensive Income Attributable To Noncontrolling Interests | $5.0M | $3.0M |
| Comprehensive Income Attributable To Owners of Parent | $481.0M | $297.0M |
| Current Assets Liabilities | $1.19B | $285.0M |
| Current Provisions | $119.0M | $122.0M |
| Current Tax Assets Current | $18.0M | $24.0M |
| Current Tax Liabilities Current | $74.0M | $78.0M |
| Decrease Increase Through Tax On Sharebased Payment Transactions | — | $1.0M |
| Deferred Tax Assets | $307.0M | $293.0M |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | $185.0M | $175.0M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | $3.0M | $3.0M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | $106.0M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | $0.48 | $0.48 |
| Dividends Received From Joint Ventures Classified As Investing Activities | $1.0M | $0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | $6.0M | -$12.0M |
| Finance Income | $83.0M | $8.0M |
| Gains Losses Arising From Difference Between Previous Carrying Amount and Fair Value of Financial Assets Reclassified As Measured At Fair Value | $1.0M | $1.0M |
| Gains Losses On Exchange Differences On Translation Before Tax | $94.0M | -$55.0M |
| Impairment Loss On Financial Assets | $1.0M | $2.0M |
| Income Taxes Refund Classified As Operating Activities | $2.0M | $0 |
| Increase Decrease In Cash and Cash Equivalents | $23.0M | -$5.0M |
| Increase Decrease Through Exercise of Options | $0 | $0 |
| Intangible Assets Other Than Goodwill | $777.0M | $774.0M |
| Interest Received Classified As Investing Activities | $6.0M | $8.0M |
| Investments In Joint Ventures | $11.0M | $11.0M |
| Issued Capital | $40.0M | $40.0M |
| Liabilities | $3.06B | $2.81B |
| Miscellaneous Other Operating Expense | $35.0M | $52.0M |
| Miscellaneous Other Operating Income | $31.0M | $63.0M |
| Net Assets Liabilities | $2.61B | $2.32B |
| Noncurrent Provisions | $40.0M | $36.0M |
| Other Comprehensive Income | $79.0M | -$62.0M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | $94.0M | -$55.0M |
| Other Comprehensive Income Net of Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income | -$13.0M | -$6.0M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -$2.0M | -$1.0M |
| Other Current Assets | $241.0M | $116.0M |
| Other Current Liabilities | $431.0M | $475.0M |
| Other Noncurrent Assets | $92.0M | $84.0M |
| Other Noncurrent Liabilities | $66.0M | $127.0M |
| Payments To Acquire Or Redeem Entitys Shares | $36.0M | $38.0M |
| Proceeds From Current Borrowings | $349.0M | $387.0M |
| Proceeds From Disposal Or Maturity of Availableforsale Financial Assets | $0 | $10.0M |
| Proceeds From Noncurrent Borrowings | $2.40B | $684.0M |
| Purchase of Treasury Shares | $36.0M | $38.0M |
| Repayments of Current Borrowings | $357.0M | $411.0M |
| Repayments of Noncurrent Borrowings | $2.09B | $536.0M |
| Research and Development Expense | $151.0M | $141.0M |
| Retained Earnings | $2.56B | $2.36B |
| Selling General and Administrative Expense | $743.0M | $671.0M |
| Share Issue Related Cost | $23.0M | $27.0M |
| Share of Profit Loss of Joint Ventures Accounted For Using Equity Method | $0 | $1.0M |
| Share Premium | $282.0M | $282.0M |
Methodology
Every line item above is a fact tagged in HIKMA PHARMACEUTICALS PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.